Mohammad M. Ansari

Mohammad M. Ansari

Auto-generated profile, based on publicly available information

Mohammad M. Ansari

Texas Tech University Health Sciences Center, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
MKMelissa L Kirkwood
Melissa L Kirkwood
EAEhrin J Armstrong
Ehrin J Armstrong
MAMohammad M Ansari
Mohammad M Ansari
AHAndrew Holden
Andrew Holden
MRMichel Reijnen
Michel Reijnen
DSDarren B Schneider
Darren B Schneider
Background: The recommendations for the use of and selection of covered stent grafts in patients with aortoiliac occlusive disease are limited. Objective: The GORE VBX FORWARD clinical study aims to demonstrate the superiority of the GORE VIABAHN VBX Balloon Expandable Endoprosthesis (VBX device) for primary patency when compared to bare metal stenting (BMS) for the treatment of complex iliac artery occlusive disease. Methods: A prospective, multicenter, randomized control study in the United States, European Union, United Kingdom, Australia, and New Zealand will enroll patients with symptomatic, complex iliac artery occlusive disease. In this study, iliac artery occlusive disease is defined as a unilateral or bilateral disease with single or multiple lesions (with >50% stenosis or chronic total occlusion) each between 4 and 11 cm in length. In an attempt to more closely match real-world practices, patients with minor tissue loss (Rutherford class 5) and patients requiring hemodialysis will be included. Baseline aortoiliac angiography will be performed to assess target lesion characteristics and determine final patient eligibility. Once the patient is confirmed and guidewires are in place across the target lesions, the patient will be randomized in a 1:1 format to treatment with either the VBX device or a BMS. The BMS can be balloon- or self-expanding and must be approved for the iliac artery occlusive disease indication. Patients, the independent core laboratory reviewers, and Clinical Events Committee members will be blinded from the assigned treatment. Dual antithrombotic medical therapy is required through a minimum of 3 months post procedure. The primary end point is 12‑month primary patency and will be adjudicated by an independent imaging core laboratory and Clinical Events Committee. Key secondary end points will be tested for superiority and include technical, acute procedural, and clinical success; changes in Ankle-brachial index; patient quality of life; primary patency; freedom from restenosis; primary-assisted patency; secondary patency; freedom from target lesion revascularizations; cumulative reintervention rate; amputation-free survival; survival; and change in Rutherford category. Study follow-up will continue through 5 years. Results: Outcomes will be reported following study completion. Enrollment is anticipated to start in October 2023. Conclusions: The results of this study will provide definitive, level 1 clinical evidence to clinicians on the optimal choice of stent device to use for the treatment of complex iliac artery occlusive disease. The FORWARD study is powered for superiority and includes only complex, unilateral, or bilateral lesions involving the common or external iliac arteries. This study is a multidisciplinary endeavor involving vascular surgery, interventional cardiology, and interventional radiology across multiple countries with a blinded core laboratory review of end points in hopes that the outcomes will be widely accepted and incorporated into practice guidelines for optimal treatment of patients with complex iliac artery occlusive disease. Trial Registration: ClinicalTrials.gov NCT05811364; https://clinicaltrials.gov/study/NCT05811364 International Registered Report Identifier (IRRID): PRR1-10.2196/51480

18 May 2023 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
GTGeoff Thomas
Geoff Thomas
ANArdalan Naghian
Ardalan Naghian
ERElwin Rutayomba
Elwin Rutayomba
LKLewis Kelly
Lewis Kelly
SDSteven Daley
Steven Daley
MAMohammad M. Ansari
Mohammad M. Ansari

8 August 2022 in Cardiovascular Revascularization Medicine
Verified
Journal Article
Closed access
SRStefan Raicevic
Stefan Raicevic
CLChristopher Le
Christopher Le
ELEn-Dien (Sam) Liao
En-Dien (Sam) Liao
ZSZhaunn Sly
Zhaunn Sly
MIMarina Iskandir
Marina Iskandir
MAMohammad M. Ansari
Mohammad M. Ansari

18 May 2023 in Journal of the Society for Cardiovascular Angiography & Interventions
Verified
Journal Article
Open access
APAnthony Pham
Anthony Pham
CPCole Pollina
Cole Pollina
ABAnthony Bruccoliere
Anthony Bruccoliere
ANArdalan Naghian
Ardalan Naghian
GTGeoff Thomas
Geoff Thomas
CWCraig M. Walker
Craig M. Walker